Recent advances in the treatment of...

Dermatological Disorders


Including valuable contributions from:

- Prof Anton Stuetz, Head, Translational Medicine & Late Phase Products, Novartis
- Dr Michael Reusch, Director, Clinical Research, Fujisawa
- Dr Elena Rizova, Associate Director, Medical Affairs, Biogen
- Dr Christopher Roberts, Director, Clinical Research, Smith & Nephew
- Dr Jean Rumsfield, Director, New Product Planning & Licensing, Fujisawa
- Leanne West, Manager, Technical & Clinical Affairs, UK/Europe, Novogen
- Dr Stephen Squinto, Executive Vice President, Head, Research, Alexion Pharmaceuticals
- Dr Kjetil Hestdal, Vice President, Research & Development, PhotoCure

A two-day intensive conference which will help you
- IDENTIFY clinical needs and new developments in dermatology
- KEEP up to date with new techniques in photodynamic therapy
- DISCOVER recent developments in tissue engineering
- FOCUS on future directions with engineered antibodies
- NETWORK with leaders in the field

www.smi-online.co.uk/dermatology.asp

Register online and receive full information on all of SMi’s conferences
Alternatively fax your registration to +44 (0)870 9090 712 or call +44 (0)870 9090 711

50% DISCOUNT
Academic Researchers will receive 50% discount on marked price
Proof of status to be sent with registration

Supported by

DrKetilHestdal,Photocure
### Introduction

#### Overview

9.10 Current concerns, clinical needs and new developments
- Advances in the treatment of immune-mediated and inflammatory skin diseases
- New biological response modifiers
- Antibody fusion proteins
- Antigen-pulsed dendritic cells for melanoma therapy
- Future directions

**Prof Thomas Luger**, Director & Chairman, Dermatology, University of Münster

### Malignant Disorders and Actinic Keratosis

#### Topical Photodynamic Therapy (PDT) System Using LEVULAN® (Aminolevulinic Acid HCl) in Dermatology

9.40 The spectrum of dermatologic disorders responsive to Levulan® PDT
- Mechanism of action of topical Levulan® PDT
- The Levulan® Kerastick and BLU-U® PDT illuminator in the treatment of actinic keratosis – an approved indication
- Additional light sources being used for Levulan® PDT
- Investigative studies of Levulan® PDT in the treatment of Bowen’s disease, Goerlin’s syndrome, and cutaneous T-cell lymphoma

**Dr Stuart Marcus**, Vice President, Scientific Affairs, DUSA Pharmaceuticals

#### Photodynamic Therapy (PDT) and Photodynamic Diagnosis (PD) for Malignant Skin Disorders

10.20 Application of Metvix® PDT – methylaminolevulinate
- Metvix® PDT – how does it work?
- Selective accumulation in cancerous cells
- Potential for photodynamic diagnosis (PD)
- Clinical experience of Metvix® PDT in treatment of BCC and AK
- Advantages regarding patient preference

**Dr Kjetil Hestdal**, Vice President, Research & Development, PhotoCure

#### Reversing Skin Damage Caused by Sunlight

11.20 Pre-clinical and clinical studies with NV-07a
- Effect on skin reddening and underlying damage leading to skin cancer
- Effect of sunlight on immune response
- Effect of NV-07a on sunlight-induced reduced immune response of skin allergic patients
- WHO alert on limitations of sun blocks regarding melanoma
- Commercial potential of NV-07a for after-sun skin repair

**Leanne West**, Manager, Technical & Clinical Affairs UK/Europe, Novogen

### Therapies for Autoimmune and Inflammatory Diseases

#### Keratinocyte Cell Signalling

12.00 Calcineurin and PKC-dependent pathways in skin disease and therapy
- Regulation of keratinocyte growth and differentiation by calcineurin and PKC
- Abnormalities of PKC and NFAT signalling in psoriasis
- Inhibition of keratinocyte calcineurin signalling by ciclosporin and tacrolimus

**Prof Nick Reynolds**, Professor, Dermatology, University of Newcastle-upon-Tyne

### Topical Immunomodulators (TIMs)

2.00 Update on tacrolimus ointment (protopic)
- Effect on cytokine release from T and mast cells
- Skin selective profile when delivered topically and orally
- Anti-inflammatory effect
- Advantages over alternative treatments
- Discovery and recent developments
- Results with eczema and psoriasis
- Approaches to marketing of non-steroid anti-inflammatories

**Prof Anton Stuctz**, Head, Translational Medicine & Late Phase Products, Novartis

### Calcineurin Inhibitors

2.40 Profile of pimecrolimus (ELIDEL®)
- Effect on cytokine release from T and mast cells
- Skin selective profile when delivered topically and orally
- Anti-inflammatory effect
- Advantages over alternative treatments
- Discovery and recent developments
- Results with eczema and psoriasis
- Approaches to marketing of non-steroid anti-inflammatories

**Dr Michael Reusch**, Director, Clinical Research, Fujisawa

### ISATX247 A Novel Calcineurin Inhibitor

3.40 Phase II trial results
- ISATX247 is a novel calcineurin inhibitor
- Preclinical and phase I trials indicate that ISATX247 is more potent and less toxic than CSA
- Phase II trial of ISATX247 for treatment of moderate to severe psoriasis
- 200 patients/80 patients 1.5 mg/kg/d/bid ISATX247; 80 patients 0.5 mg/kg/d/bid ISATX247; 40 patients on placebo
- 3 month duration
- Trial results to be reported

**Dr Randall Yatscoff**, President & Chief Operating Officer, Isotechnika

### Novel Approach to Drug Target Identification

4.20 Application to psoriasis and other skin disorders
- Limitations of conventional therapies in psoriasis
- Identification of molecular switch genes in normal skin tissue
- Target genes for wound healing and dermatological disorders
- Real time PCR for target gene verification
- Use of expression vectors and recombinant proteins to ‘jack up’ genetic activity
- Application of technology to psoriasis, atopic dermatitis, vitiligo and chronic wounds

**Dr Andreas Goppelt**, Chief Scientific Officer, SWITCH Biotech

5.00 Chairman’s Closing Remarks and Close of Day One
Re-registration & Coffee

9.00 Chairman’s Opening Remarks
Prof Richard Camp, Professor of Dermatology, University of Leicester

TARGETING MEMORY-EFFECTOR T CELLS

9.10 Recombinant fusion protein – alefacept (Amevive)
- Role of T cells in pathogenesis of psoriasis
- Biologic strategies for treating psoriasis
- Mode of action of alefacept (Amevive) (specific targeting of CD45Ro+ T memory-effector cells)
- Clinical trials
- Effect on treatment of psoriasis
- Durability of remission

Dr Elena Rizova, Associate Director, Medical Affairs, Biogen

INHIBITION OF COMPLEMENT IN THE TREATMENT OF DERMATOMYOSITIS

9.40 Anti-complement C5 antibody shows utility for the treatment of dermatomyositis patients
- Limitations of current treatments of dermatomyositis
- Antibody/complement component in dermatomyositis
- Eculizumab; anti-C5 monoclonal antibody
- Complement blockade in disease models
- Advantages of anti-complement therapy in dermatomyositis
- Dermatomyositis clinical trial results with Eculizumab

Dr Stephen Squinto, Executive Vice President, Head, Research, Alexion Pharmaceuticals

ACNE, ROSACEA AND SKIN INFECTIONS

10.20 NEW TREATMENTS FOR FUNGAL INFECTIONS
- Needs in the field of fungal disease
- New drugs – triazoles, cell wall inhibitors
- Combination therapy
- Future developments eg melanin biosynthesis inhibitors
- Drug resistance

Prof Rod Hay, Chairman, International Foundation of Dermatology

11.00 Morning Coffee

NEW DEVELOPMENT FOR ACNE

11.20 Dapson topical gel
- Potent antibiotic and independent anti-inflammatory activity
- New proprietary SMP topical drug delivery
- Reduction of inflammatory lesions
- Phase III studies
- Comparison with other treatments

Dr Jean Rumsfield, Director, New Product Planning & Licensing, Fujisawa

TREATMENT OF CHRONIC SKIN WOUNDS

TRANSFER OF LIVING SKIN CELLS TO WOUND BED

12.00 Developments towards a living bandage
- Surgical needs and marketing opportunities
- Plasma technology for carrier devices
- Advantages of CellTran approach
- Patient benefits as shown by clinical trials
- Ultimate goals

Prof Sheila MacNeil, Director, CellTran

TREATMENT OF CHRONIC SKIN WOUNDS

12.40 Networking Lunch

CELL-BASED THERAPEUTIC SOLUTIONS FOR TREATMENT OF SKIN FAILURE

2.00 Allox – an off-the-shelf allogeneic cell-based product
- Product description
- Results of clinical trials
- Complement to Epiderm™

Dr Rene Goedkoop, Clinical Director, Modex Therapeutics

NEW DEVELOPMENT FOR ACNE

3.20 Afternoon Tea

IDENTIFICATION OF NOVEL THERAPEUTICS FOR THE TREATMENT OF CHRONIC ULCERS

3.40 A functional genomic approach
- Gene profiling in tissue
- Functional studies in cell culture
- Target validation in animal models

Dr Michaela Bittner, Associate Director, Research & Development, SWITCH Biotech

LIVING HUMAN DERIVED DERMAL REPLACEMENT

4.20 Deficiencies in repair across chronic wounds and need for advanced therapies
- Other chronic wound experiences
- Foot ulcers in diabetes
- Culture of human dermal fibroblasts into a biosynthetic scaffold
- Generation of 3-dimensional human dermis containing metabolically active living cells
- Safety features
- New developments

Dr Christopher Roberts, Director, Clinical Research, Smith & Nephew

Chairman’s Closing Remarks and Close of Conference

5.00
## REGISTRATION FORM

**Conference:** 4th & 5th December 2002, The Hatton, London

### 50% DISCOUNT

Academic Researchers will receive 50% discount on marked price

Proof of status to be sent with registration

<table>
<thead>
<tr>
<th>Unique Reference Code</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
</tr>
</tbody>
</table>

### CONFERENCE FEE

- **Option A** Conference only
  - Fee: £199.00
  - VAT: £19.32
  - Total: £218.32

- **Option B** Conference only
  - Fee: £545.50
  - VAT: £66.16
  - Total: £611.66

### How to register:

**By mail:** Complete and return your signed Registration Form together with your cheque to: SMi Conferences Ltd, 1 New Concordia Wharf, Mill St, London, SE1 2BB

**By fax:** Complete and fax your signed Registration Form with your credit card details to +44 (0) 870 9090 712

**By internet:** Complete your Registration Form online with your credit card details at www.smi-online.co.uk/dermatology.asp

### How to contact us:

- **Telephone:** +44 (0) 870 9090 711
- **Fax:** +44 (0) 870 9090 712
- **Email:** customer_services@smi-online.co.uk
- **Web:** www.smi-online.co.uk/dermatology.asp

### How we will contact you:

SMi Conferences Ltd's preferred method of communication is by email and phone. Please ensure you complete the Registration Form so that we can contact you. We will use postal services on a request basis only.

### Venue:

The Hatton, 51-53 Hatton Garden, London, EC1N 8HN.

The Hatton is SMi Conferences Ltd's bespoke state of the art conference venue and has excellent transport links to all London airports, with train and tube stations nearby. There are also three NCP car parks in close proximity. Full details will be included in your conference joining pack.

### We can arrange your travel, accommodation, transfers and insurance.

The SMi JVT team are available to make your journey and stay during the conference as hassle free and smooth as possible. SMi JVT can book your accommodation, flights, transfers and arrange insurance all at the best possible rate. Please contact us on +44 (0) 870 9090 713 for more information or visit our website www.smi-online.co.uk/travel.asp. Please book early to get the full advantage of our travel packages.

### Payment terms:

SMi Conferences Ltd require the full amount to be settled prior to the event taking place. SMi Conferences Ltd reserves the right to refuse entry to any customer who has not paid their invoice. A credit card guarantee may be requested if full payment has not been received.

### Methods of payment:

Payment must be in sterling. You can pay by cheque drawn on a UK bank, payable to SMi Conferences Ltd or by bank transfer to HSBC Account No: 11364057 Sort Code: 40 06 21 For overseas customers please use SWIFT CODE MIDLGB22 28 Borough High St, London SE1 1YB, or by credit card. Please complete the Registration Form. When making payments please quote delegate's name and conference and/or product.

### Interest:

SMi Conferences Ltd reserves the right to charge interest on any unpaid invoices.

### Alteration to invoices:

Any alterations to an invoice, excluding substitutions/names changes, requested by the customer will incur an administration fee of £50 and will be charged to the customer by credit card prior to the amendment being made.

### Cancellations/substitutions and name changes:

All bookings carry a 50% liability after the booking has been made, by post, fax, email or web. There will be no refunds for cancellations received on or after one month before the start of the conference (e.g. cancellation on or after 20th January for a conference starting on 4th February). If you decide to cancel after this date the full invoice remains payable. Conference notes which are available on the day will be sent to you. Unfortunately we are not able to transfer places between conferences and conferences and executive briefings. However, if you are unable to attend the event you may make a substitution/name change at any time as long as we are informed in writing by email, fax or post. Name changes and substitutions must be from the same company and are not transferable between companies or countries.

### Indemnity:

SMi Conferences Ltd reserve the right to change the conference/executive briefing content, timing, speakers or venue without notice. The event may be postponed or cancelled due to acts of terrorism, industrial action, acts of God or any event beyond the control of SMi Conferences Ltd. If such a situation arises we will endeavour to reschedule the event. However, SMi Conferences Ltd cannot be held responsible for any cost, damage or expenses which may be incurred by the customer as a consequence of the event being postponed or cancelled.

### Data Protection:

SMi Group Ltd gathers and manages data in accordance with the Data Protection Act 1988. The information about you contained on this form may be used to update you on SMi Group products and services via post, telephone, fax or e-mail, unless you state that you do not want us to do so. We may also share your data with external companies offering complementary products or services. If you wish for your details to be amended, suppressed or not passed on to any external third party, please send your request to Database Manager, SMi Group Ltd, No 1 New Concordia Wharf, Mill St, London, SE1 2BB. Alternatively, you can visit our website www.smi-online.co.uk/updates and amend your details via our secure online system. If you wish to amend your details via email please ensure you include the 8 digit “unique reference number”. Please allow approximately 30 days for your removal or update request to be applied to our database. Following your removal or update request, you may receive additional pieces of communication from SMi Group during the transitional period, whilst the changes are applied.

### VAT:

VAT will be charged at the local rate on each conference. Delegates may be able to recover VAT incurred by contacting Eurocash Corporation plc (0)1273 325000, eurocash@eurocashvat.com. Eurocash are specialists in recovering cross border VAT.